文献速递贫血与红细胞疾病MDS 与骨髓增殖性肿瘤

Momelotinib逆转输血依赖并抑制骨髓纤维化患者铁调素

ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial.
PubMed 文献 · Blood Adv · 2020-01-01

这项2期开放标签研究纳入41例输血依赖的骨髓纤维化患者,评估ACVR1/JAK1/JAK2抑制剂momelotinib的作用机制。41%患者达到输血独立应答,且治疗导致铁调素持续下降、铁利用和红细胞生成改善,提示其减少输血依赖的机制。

要点

  • Momelotinib在41例输血依赖骨髓纤维化患者中输血独立应答率达41%。
  • 治疗导致血铁调素急性持续下降,伴铁利用和红细胞生成标志物改善。
  • 常见不良事件为咳嗽、腹泻、恶心,≥3级不良事件最常见为贫血和中性粒细胞减少。

核心结论

  • Momelotinib治疗降低铁调素并改善铁代谢和红细胞生成,为减少输血依赖提供机制解释。

研究设计与样本

  • 2期开放标签转化生物学研究(NCT02515630),纳入41例输血依赖的骨髓纤维化患者。

主要发现

  • 17例(41%;95%CI 26%-58%)达到输血独立应答(TI-R),其中14例(34%;95%CI 20%-51%)在24周内达到。
  • 78%的输血无应答患者输血需求较基线降低≥50%且持续≥8周。
  • 每日momelotinib治疗导致血铁调素急性持续下降,伴铁利用和红细胞生成标志物增加。
  • 与TI-R相关的基线特征包括较低炎症和铁调素水平,以及较高的红细胞生成和骨髓功能标志物。

临床怎么用

  • 对于输血依赖的骨髓纤维化患者,momelotinib可能通过抑制铁调素改善贫血并减少输血需求。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Momelotinib (MMB) is a JAK1/2 and ACVR1 inhibitor with demonstrated clinical activity in all 3 hallmarks of myelofibrosis (MF): anemia, constitutional symptoms, and splenomegaly. In this phase 2 open-label translational biology study (NCT02515630) of 41 transfusion-dependent patients with MF, we explored mechanisms underlying the favorable activity of MMB on MF-associated iron-restricted anemia, including its impact on serum hepcidin levels, and markers of iron storage and availability, erythropoiesis, and inflammation. A transfusion-independent response (TI-R), defined as red blood cell transfusion independence (TI) ≥12 weeks at any time on study, occurred in 17 patients (41%; 95% confidence interval [CI], 26%-58%), including 14 patients (34%; 95% CI, 20%-51%) who achieved TI-R by week 24. In addition, 78% of TI nonresponse (TI-NR) patients achieved a ≥50% decrease in transfusion requirement for ≥8 weeks. Adverse events (AEs) were consistent with previous studies of MMB in MF, with cough, diarrhea, and nausea as the most common. Twenty-one patients experienced grade ≥3 AEs, most commonly anemia and neutropenia. Consistent with preclinical data, daily MMB treatment led to an acute and persistent decrease in blood hepcidin associated with increased iron availability and markers of erythropoiesis. Baseline characteristics associated with TI-R were lower inflammation and hepcidin as well as increased markers of erythropoiesis and bone marrow function. Overall, the study demonstrates that MMB treatment decreases hepcidin in conjunction with improving iron metabolism and erythropoiesis, suggesting a mechanistic explanation for the reduced transfusion dependency observed in transfusion-dependent MF patients treated with MMB, thereby addressing the key unmet medical need in the MF population.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Oh ST, Talpaz M, Gerds AT, et al. ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial. Blood Adv. 2020. PMID: 32915978. doi:10.1182/bloodadvances.2020002662

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。